Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their ...
Wedbush analyst David Nierengarten reiterates Nuvalent (NASDAQ:NUVL) with a Outperform and maintains $99 price target.
Nuvalent (NASDAQ:NUVL) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.68) by...
Jefferies analyst Roger Song initiates coverage on Nuvalent (NASDAQ:NUVL) with a Buy rating and announces Price Target of $97.
Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-typ...
Leerink Partners analyst Andrew Berens upgrades Nuvalent (NASDAQ:NUVL) from Market Perform to Outperform and raises the pric...
JP Morgan analyst Anupam Rama maintains Nuvalent (NASDAQ:NUVL) with a Overweight and raises the price target from $68 to $98.
Guggenheim analyst Kelsey Goodwin assumes Nuvalent (NASDAQ:NUVL) with a Buy rating and announces Price Target of $99.
